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Background: Corticosteroids (CS) have limited efficacy in the treatment of chronic obstructive 
pulmonary disease (COPD). p38 mitogen-activated protein kinase (MAPK) activation is 
increased in lung macrophages of COPD. We investigated whether p38 MAPK inhibition 
can modulate CS insensitivity of peripheral blood mononuclear cells (PBMCs) from patients 
with COPD.
Methods: PBMCs from patients with COPD (n=8) or healthy smokers (n=8) were exposed to 
lipopolysaccharide (LPS) with a selective p38 MAPK inhibitor (GW856553; 10-10–10-6 M), 
with dexamethasone (10-10–10-6 M), or with both. Phosphorylated glucocorticoid receptor (GR) 
was measured by Western blot.
Results: Baseline (P,0.01) and LPS-induced (P,0.05) CXCL8 release was greater in PBMCs 
from COPD compared to healthy smokers. Inhibition of LPS-induced CXCL8 release by dexa-
methasone (10-6 M) was reduced, and baseline and LPS-induced p38 MAPK activation increased 
in PBMCs of COPD. GW856553 (10-9 and 10-10 M) synergistically increased the inhibitory 
effect of dexamethasone (10-8 and 10-6 M) on LPS-induced CXCL8 release in COPD. Similar 
results were obtained for IL-6 release. GW856553 inhibited dexamethasone- and LPS-activated 
phosphorylation of serine 211 on GR. CS insensitivity in COPD PBMCs is reversed by inhibition 
of p38 MAPK activity, partly by preventing phosphorylation of GR at serine 211.
Conclusion: p38 MAPK inhibition may be beneficial in COPD by restoring CS sensitivity.
Keywords: glucocorticoid receptor, p38 mitogen-activated protein kinase
Introduction
Chronic obstructive pulmonary disease (COPD) is a progressive disease affecting 
both the airways and lungs, largely caused by cigarette smoking. It is a major cause of 
global morbidity and mortality, predicted to become the third leading cause of death 
by 2020.1 COPD is characterized by chronic airflow obstruction of the small airways 
that is poorly responsive to β
2
-agonist bronchodilators and corticosteroids (CS). The 
chronic airway inflammatory response in COPD is characterized by a predominance of 
neutrophils and macrophages in the lung.2 Increased activation of the proinflammatory 
transcription factor, nuclear factor-κB, has been reported in bronchial biopsies of stable 
COPD patients and in sputum macrophages of patients with COPD exacerbation.3 There 
is also evidence of systemic inflammation with raised serum levels of inflammatory 
biomarkers such as interleukin (IL)-6 and C-reactive protein (CRP).4
Inhaled CS (ICS) are recommended anti-inflammatory treatment for COPD 
patients with a forced expiratory volume in 1 second (FEV
1
) of less than 60% predicted 
and who are prone to frequent exacerbations. ICS are combined with long-acting 
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β-agonists (LABA) when symptoms persist or worsen. CS 
diffuse across the plasma membrane, and bind to and activate 
the glucocorticoid receptor (GR) in the cytoplasm, which 
then translocates into the nucleus, where it can either activate 
the transcription of anti-inflammatory genes or suppress 
proinflammatory gene expression. GR phosphorylation at 
serine (Ser) 203, Ser211, and Ser226 has been reported to be 
enhanced upon binding of CS to GR, linking GR phosphoryla-
tion with transcriptional activity.5 However, hyperphosphory-
lation of GR can have a detrimental effect on ligand binding6 
as well as on nuclear DNA and protein interactions.7
The p38 MAPK family of serine/threonine protein 
kinases consist of four isoforms (p38α, p38β, p38γ, and 
p38δ) that are activated by inflammatory stimuli that 
include Toll-like receptor agonists.8 Activated p38 MAPK 
phosphorylates a number of intracellular proteins, including 
transcription factors such as GR,9 and regulates the transla-
tion and the stability of inflammatory mRNAs.10 The p38α 
isoform is expressed in endothelial, immune, and inflamma-
tory cells and regulates the expression of the proinflamma-
tory cytokines TNF-α, IL-1β, CXCL8, and IL-6.11 Alveolar 
macrophages from patients with COPD express a greater 
degree of activation of p38 MAPK, as compared to cells 
from healthy smokers,12 and are less sensitive to inhibition 
of CXCL8 and GM-CSF release13 by dexamethasone. Cross 
talk between the p38 MAPK signaling pathways and GR 
has been reported, such as Ser211 on GR being a potential 
substrate for p38 MAPK.14
p38 MAPK inhibitors suppress inflammatory media-
tor release from alveolar macrophages of patients with 
COPD.15 We now extend these in vitro studies to peripheral 
blood mononuclear cells (PBMCs) of patients with COPD. 
Because exacerbations of COPD are frequently caused by 
bacterial infections,16 we used lipopolysaccharide (LPS) 
to activate PBMCs. Although CS are used in treating 
exacerbations of COPD, their anti-inflammatory response 
is limited.
Anti-inflammatory therapies for COPD, such as ICS, 
may provide partial benefit, although there is a degree of 
CS insensitivity in these patients.17 There is an unmet need 
to develop novel anti-inflammatory therapies that could 
slow or stop disease progression, but one other approach 
would be to reverse CS insensitivity. To explore a poten-
tial role for p38 MAPK activation in CS insensitivity, 
we examined whether an inhibitor of p38 MAPK could 
improve the anti-inflammatory ability of dexamethasone 
to suppress cytokine release in PBMCs from patients with 
COPD in response to LPS stimulation. We studied the 
effect of p38 MAPK activation on the phosphorylation 
status of GR at Ser211.
Methods
study participants
Patients with COPD were recruited from the clinics of the 
Royal Brompton Hospital (London, UK), and smokers were 
recruited by local advertisement (Table 1). Patients with 
COPD were diagnosed on the basis of a ratio of FEV
1
/forced 
vital capacity ,0.7 with a cigarette-smoking history of more 
than 10 pack-years, and classified according to the Global ini-
tiative of Chronic Obstructive Lung Disease (GOLD) criteria 
based on the predicted FEV
1
. Healthy smokers had a cigarette 
smoking history of .10 pack-years but had an FEV
1
/forced 
vital capacity ratio .70% and FEV
1
 . 80% predicted. The 
study protocol was approved by the Ethics Committee of 
Royal Brompton and Harefield NHS Trust/National Heart and 
Lung Institute, London, UK (09/H0708/19). All volunteers 
gave their written informed consent.
Isolation and stimulation of PBMCs
PBMCs were isolated as previously described.18 PBMCs 
(7.5×105 cells/well) were stimulated with LPS (10 ng/mL), 
and with or without dexamethasone (10-10–10-6 M) or with 
or without GW856553 (10-10–10-6 M). Supernatants were 
removed 18 hours later and analyzed for CXCL8 or IL-6 by 
enzyme-linked immunosorbent assay (R&D Systems, Inc., 
Minneapolis, MN, USA).
p38 MaPK inhibitor
GW856553 (GlaxoSmithKline plc, London, UK) is a p38 
MAPK inhibitor of the nicotinamide class, with a p38α 
pK
i
 =8.1 and a p38β pK
i
 =7.6.19 It has a pIC
50
 =7.6 in block-
ing LPS-induced TNFα production in human whole blood 
and is 100-fold selective for p38 MAPK when tested against 
a panel of 67 other kinases.19
Table 1 Clinical characteristics of subjects
COPD Smokers
n 13 8
age (years) 66±2 55±3
sex (male:female) 8:3 6:4
FeV1 (% of predicted) 49±5** 88±8
FeV1/FVC (%) 63±4** 90±6
smoking history (pack years) 66±17** 36±8
Notes: results shown as mean ± standard error. **P,0.01 compared to healthy 
smokers without obstruction.
Abbreviations: COPD, chronic obstructive pulmonary disease; FeV1, forced 
expiratory volume in one second; FVC, forced vital capacity.
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Western blotting
Protein membranes were incubated with rabbit antibody for anti-
phospho-p38 followed by anti-rabbit-horseradish peroxidase 
antibody. Antibody-bound proteins were visualized by ECL or 
ECL plus (GE Healthcare UK Ltd, Little Chalfont, UK). The 
membranes were then reprobed with rabbit anti-total p38 (Cell 
Signaling Technology, Inc., Danvers, MA, USA) or with mouse 
anti-β-actin monoclonal antibody (Santa Cruz  Biotechnology 
Inc., Dallas, TX, USA) to control for protein loading. Relevant 
band intensities were quantified by scanning densitometric 
analysis (VisionWorks V7; UVP Corp, Upland, CA, USA).
Data analysis
Cytokine release induced by LPS with or without dexametha-
sone or p38 MAPK inhibitor was calculated by subtraction of 
baseline release. The release of each cytokine following dexam-
ethasone plus LPS was calculated as a percentage of cytokine 
release following LPS stimulation alone. We performed 
Spearman’s rank correlations to determine the relationships 
between baseline or LPS-induced CXCL8 release and FEV
1
. CS 
responsiveness between COPD patients and healthy smokers 
was compared using the Mann–Whitney U test. Concentration-
dependent responses were examined using one-way analysis of 
variance (Kruskal–Wallis test) followed by a Dunn’s Multiple 
Comparison test. Results are expressed as mean ± standard 
error. P,0.05 was taken as a significant difference.
Results
Baseline data of patients with COPD and healthy smokers 
are presented in Table 1. Patients with COPD had severe 
airflow obstruction (P,0.01).
regulation of CXCl8 by dexamethasone
Baseline and LPS-induced CXCL8 release were higher 
in patients with COPD compared to healthy smokers 
(P,0.01 and P,0.05, respectively; Figure 1A). Base-
line and induced CXCL8 release correlated inversely 
with FEV
1
 (r=-0.55, P=0.04; and r=-0.71, P=0.008, 
respectively; Figure 1B and C). Dexamethasone inhibited 
CXCL8 release in a concentration-dependent manner 
(10-10–10-6 M) in the COPD (P,0.001, Kruskal–Wallis) 
and healthy-smoker (P,0.001, Kruskal–Wallis) groups, 
with a signif icantly reduced suppression in PBMCs 
of patients with COPD compared to healthy smokers 
(Figure 2A). Dexamethasone (10-6 M) led to a maximal 
suppression of LPS-induced CXCL8 release in PBMCs 
of patients with COPD of 41%±3.5% compared to 
58.9%±4.5% in healthy smokers (P,0.01).
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Figure 1 Baseline and lPs-induced CXCl8 release from PBMCs of patients with 
COPD and healthy smokers.
Notes: (A) Comparison of baseline (ns) and lPs-induced CXCl8 release in PBMCs 
from healthy smokers (n=10) or COPD patients (n=11). Cells were stimulated with 
lPs (10 ng/ml) for 24 hours. CXCl8 release was determined by enzyme-linked 
immunosorbent assay. horizontal bar represents median. *P,0.05, **P,0.01, 
***P,0.001. (B) spearman’s rank correlation between baseline CXCl8 release 
and FeV1. (C) spearman’s rank correlation between lPs-induced CXCl8 
release and FeV1.
Abbreviations: COPD, chronic obstructive pulmonary disease; FeV1, forced 
expiratory volume in 1 second; lPs, lipopolysaccharide; ns, not stimulated; 
PBMCs, peripheral blood mononuclear cells.
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effect of p38 MaPK inhibitor  
on lPs-induced CXCl8 release
GW856553 inhibited LPS-induced CXCL8 release in a 
concentration-dependent manner (10-10–10-6 M) in both the 
COPD (P,0.0001, Kruskal–Wallis) and healthy-smoker 
(P,0.0001, Kruskal–Wallis) groups. A maximal suppression 
of 47.2%±6.7% (half maximal inhibitory concentration [IC
50
] 
9×10-6 M) and 53.8%±9.2% (Figure 2B) from PBMCs of 
patients with COPD and healthy subjects, respectively, was 
achieved at a concentration of 10-6 M. There was no differ-
ence in suppression in PBMCs from patients with COPD 
compared to that in healthy smokers.
p38 MaPK activity
We compared induced-p38 MAPK activity at 30 minutes 
poststimulation in PBMCs of patients with COPD and 
healthy smokers. p38 phosphorylation in COPD was higher 
than in smokers both at baseline (P,0.05; Figure 3A and B) 
and after LPS stimulation (P,0.05; Figure 3C).
effect of dexamethasone and gW856553 
on CXCl8 and Il-6 release
For all concentrations of dexamethasone, the addition 
of GW856553 resulted in a concentration-dependent 
improvement in the suppressive effect of the glucocorti-
coid. The effect of dexamethasone at 10-6 M (Figure 4A) 
in suppressing CXCL8 release was increased in the pres-
ence of GW856553 (10-10–10-6 M) (P,0.0001), with a 
maximal suppression of 80.1%±4% (IC
50
 2.6×10-11 M) with 
GW856553 at 10-6 M compared to 47.2%±6.7% suppression 
with dexamethasone alone (P,0.001). With GW856553 at 
10-9 M and 10-10 M, which alone has a suppressive effect 
of less than 3%, CXCL8 suppression by dexamethasone 
(10-6 M) was greater at 65.2%±4.1% (P,0.001) and 
57.4%±5.5% (P,0.01), respectively (Figure 4B). At dexam-
ethasone 10-8 M, the suppressive effect was also increased 
by GW856553 (P,0.001), with maximal suppression with 
GW856553 (10-6 M) of 67.5%±5.6% (IC
50
 1.4×10-9 M) 
as compared to 20.2%±4.1% with dexamethasone alone. 
Similar effects were observed with dexamethasone at a 
concentration of 10-9 M in combination with GW856553 
(IC
50
 3.7×10-7 M).
Improvements in the suppressive effects of dexametha-
sone by GW856553 were also observed for IL-6 release 
(Figure 5A). Compared with the effect of GW856553 alone, 
the combination of dexamethasone at 10-6 M and GW856553, 
at 10-9 M and 10-10 M (Figure 5B), increased maximal sup-
pression of IL-6 (62%±7% versus 9.1%±2.0% and 51%±7% 
versus 10.3%±2.8%, respectively; P,0.001).
GW856553 was a potent steroid-sparing agent: the 
maximal suppression of CXCL8 release obtained with the 
highest concentration of dexamethasone (10-6 M) can also be 
achieved by a 100-fold lower concentration of dexamethasone 
(10-8 M) in the presence of GW856553 (10-9 M).
p38 MaPK inhibition reverses  
Cs insensitivity in COPD
The maximal CS suppression achieved in combination with 
GW856553 (10-6 M) was 87.1%±3.1% in PBMCs from 
healthy smokers, which is not different from PBMCs from 
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Figure 2 relative corticosteroid insensitivity in PBMCs of COPD patients.
Notes: PBMCs from healthy smokers (, n=8) and COPD patients (•, n=11) were pretreated with (A) dexamethasone or (B) gW856553 for 1 hour and then stimulated 
with lPs (10 ng/ml) for 24 hours. CXCl8 release was determined by enzyme-linked immunosorbent assay. (A) Inhibition of lPs-induced CXCl8 release from PBMCs of 
healthy smokers and COPD patients by dexamethasone. (B) Inhibition of lPs-induced CXCl8 release from PBMCs of healthy smokers and COPD patients by the p38α 
MaPK inhibitor, gW85655. **P,0.01 compared to healthy smokers.
Abbreviations: COPD, chronic obstructive pulmonary disease; Dex, dexamethasone; lPs, lipopolysaccharide; PBMCs, peripheral blood mononuclear cells.
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COPD patients (80.1%±4%; Figure 6). For all concentrations 
of GW856553, there was an equivalent improvement in the 
suppressive effect of dexamethasone (10-6 M) in PBMCs 
from both patients with COPD and healthy smokers. There 
was no difference in the suppressive effect of dexamethasone 
between COPD and healthy smokers in the presence of the 
p38 MAPK inhibitor.
p38 MaPK phosphorylation of ser211 
on gr
To explore a mechanism by which GW856553 improves the 
suppressive effects of dexamethasone, we examined the phos-
phorylation of Ser211 on GR in response to dexa methasone 
and/or LPS. PBMCs of patients with COPD were pretreated 
with dexamethasone and/or GW856553 (both at 10-6 M) 
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Figure 3 Comparison of baseline and induced p38 MaPK activation in PBMCs of COPD patients and healthy smokers.
Notes: Phosphorylated and total p38 MaPK expression were determined in whole-cell protein extracts by Western blotting and were normalized to β-actin. The ratio of 
phospho-p38 MaPK to total p38 MaPK expression, determined by Western blotting and subsequent densitometric analysis, was taken as a measure of p38 MaPK activation. 
(A and B) Baseline phosphorylated and total p38 MaPK expression in PBMCs of healthy smokers and COPD patients. (C) lPs-induced p38 MaPK activation in PBMCs of 
healthy smokers and COPD patients. PBMCs were stimulated with lPs (10 ng/ml) for 30 minutes. (B and C) horizontal bar represents median. *P,0.05.
Abbreviations: C, COPD; COPD, chronic obstructive pulmonary disease; lPs, lipopolysaccharide; PBMCs, peripheral blood mononuclear cells; s, healthy smoker.
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for 1 hour and then stimulated with LPS (10 ng/mL) for 
30 minutes. Dexamethasone induced a fourfold increase in 
Ser211 phosphorylation over baseline (P,0.05; Figure 7A), 
which was prevented by GW856553 (P,0.05; Figure 7B). 
LPS with dexamethasone induced a sixfold increase in 
phosphorylation of Ser211 over baseline (P,0.05) while 
GW856553 suppressed this induction to the level observed 
for dexamethasone alone (P,0.05).
Discussion
PBMCs of patients with COPD have higher baseline and 
induced CXCL8 release compared with healthy smokers, 
which correlates with impaired lung function. We showed 
relative CS insensitivity in PBMCs of patients with COPD 
when compared to PBMCs from healthy smokers, together 
with heightened p38 MAPK activation at both baseline and 
in response to LPS stimulation. To investigate the interaction 
between p38 MAPK activation and CS, we studied the effect 
of the selective p38 MAPK inhibitor, GW856553, and showed 
an enhancement of the suppressive effects of dexamethasone 
in PBMCs from patients with COPD at very low concentra-
tions of GW856553, which had minimal effects alone, on 
CXCL8 release. This enhancement in the inhibitory effects 
of dexamethasone was synergistic. p38 MAPK inhibition also 
reversed CS insensitivity because, over the complete range 
of GW856553 concentrations used, the improvement in the 
suppressive effects of dexamethasone (10-6 M) in COPD 
was identical to that achieved in healthy smokers. Our data 
is supported by a recent study that showed that a p38 MAPK 
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Figure 4 effect of p38 MaPK inhibition on dexamethasone-mediated suppression of 
lPs-induced CXCl8 release from PBMCs of COPD patients.
Notes: Cells were pretreated with dexamethasone or gW856553 alone or 
in combination for 1 hour and then stimulated with lPs (10 ng/ml) for 24 hours. 
(A) Inhibition of lPs-induced CXCl8 release from PBMCs of COPD patients by 
the p38 MaPK inhibitor, gW856553 (n=8), in the presence of dexamethasone, and 
(B) by dexamethasone in the presence of gW856553. Data shown as mean ± standard 
error. *P,0.05, **P,0.01, ***P,0.001 compared to dexamethasone, alone.
Abbreviations: COPD, chronic obstructive pulmonary disease; Dex, 
dexamethasone; gW, gW856553; lPs, lipopolysaccharide; PBMCs, peripheral 
blood mononuclear cells.
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Figure 5 effect of p38 MaPK inhibition on dexamethasone-mediated suppression of 
lPs-induced Il-6 release from PBMCs of COPD patients.
Notes: Cells were pretreated with dexamethasone or gW856553 alone or in 
combination for 1 hour and then stimulated with lPs (10 ng/ml) for 24 hours. 
(A) Inhibition of lPs-induced Il-6 release from PBMCs of COPD patients by the 
p38 MaPK inhibitor, gW856553 (n=8), in the presence of dexamethasone, and 
(B) by dexamethasone in the presence of gW856553. Data shown as mean ± standard 
error. *P,0.05, **P,0.01, ***P,0.001 compared to dexamethasone alone.
Abbreviations: COPD, chronic obstructive pulmonary disease; Dex, dexa-
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mononuclear cells.
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inhibitor, in combination with dexamethasone, caused a 
greater suppression of gene expression induced by LPS in 
alveolar macrophages.15
An increase in the number of macrophages expressing 
phosphorylated p38 MAPK in lung tissues from patients 
with COPD has been reported.12 In a study of oral p38 
MAPK inhibitor GW856553 (Losmapimod) in patients with 
COPD, there was a reduction in plasma fibrinogen by 11%, 
with a trend towards lower CXCL8, IL-6, and CRP plasma 
levels.20 This effect could result from an inhibitory effect of 
GW856553 on the release of CXCL8 and IL-6 from circulat-
ing PBMCs, as p38 MAPK activation is reported to enhance 
CXCL8 mRNA stability and reduce protein turnover,20 
leading to increased CXCL8 release.21 Cigarette-smoke-
induced CXCL8 release from airway epithelial cells in vitro 
is also attenuated by a p38 MAPK inhibitor (SB203580) at 
both transcriptional and translational levels.22 Using another 
p38 MAPK inhibitor (PH-797804), a decrease in serum 
C-reactive protein in moderate to severe COPD patients was 
observed, despite these patients already being treated with 
ICS. This would indicate an improvement in CS insensitiv-
ity, as illustrated by an improvement in anti-inflammatory 
effect by p38 MAPK inhibition above that provided by ICS/
LABA alone.23 In rodent models of tobacco-smoke-induced 
inflammation, a p38 inhibitor given therapeutically or pro-
phylactically was able to inhibit tobacco-smoke-induced 
inflammatory responses and increases in CXCL8 produc-
tion,24 whereas dexamethasone was ineffective.25
Our data show the potential downstream effects of height-
ened p38 MAPK activation, either at baseline or in response 
to LPS stimulation, can lead to a reduction in the effective-
ness of CS. Heightened p38 MAPK activity may result in the 
failure of CS to suppress inflammation in severe asthma,18 
and we now report similar findings in COPD. We also report 
an increase in baseline p38 MAPK activity which has been 
shown to have an effect on GR function. For example, in 
airway smooth muscle cells, baseline levels of p38 MAPK 
activation maintains unliganded GR in an inactive state.26 
Thus, an increase in baseline p38 MAPK activation, as 
reported in our study, may induce CS insensitivity in COPD 
by decreasing the ability of GR to switch from an inactive 
to active state in response to CS.
We also showed that CS-dependent phosphorylation 
of Ser211, on the human GR, is a p38 MAPK-dependent 
process. However, we did not determine whether the effect 
is a result of direct or indirect action of p38 MAPK on GR 
Ser211. GR phosphorylation is enhanced upon glucocorti-
coid ligand binding, suggesting a link between GR hormone-
dependent phosphorylation and transcriptional activity.5 
The human GR phosphorylation sites, Ser203, Ser211, and 
Ser226, lie within the N-terminal AF1 region of the receptor. 
GR Ser203 and Ser226 are phosphorylated in both the 
absence and presence of agonists, whereas phosphorylation 
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ser211 on the glucocorticoid receptor in PBMCs of COPD patients.
Notes: Cells were pretreated with dexamethasone (10-6 M) alone or in combination 
with gW856553 (10-6 M) for 1 hour and then stimulated with lPs (10 ng/ml) 
for 30 minutes. Phosphorylated ser211 in whole-cell protein extracts (n=5) was 
determined by Western blotting (A), followed by densitometric analysis (B) and 
was normalized to β-actin. (B) Data shown as mean ± standard error. #P,0.05 
compared to ns. *P,0.05.
Abbreviations: COPD, chronic obstructive pulmonary disease; Dex, dexamethasone; 
gr, glucocorticoid receptor; gW, gW856553; lPs, lipopolysaccharide; ns, unsti-
mulated control; PBMCs, peripheral blood mononuclear cells; ser211, serine 211.
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of Ser211 is only observed in a ligand-dependent manner. 
Recent studies have suggested that Ser211 is not a pri-
mary target for p38 MAPK activity27 and that p38 MAPK 
primarily phosphorylates Ser134 in a ligand-independent 
manner.28 In airway smooth muscle cells, Bouazza et al 
showed that Ser203 but not Ser211 is a direct substrate for 
p38 MAPK29 and suggested that blockade of p38 MAPK, 
or mutation of Ser211 to alanine, results in a decrease in 
Ser203 phosphorylation with a concomitant increase in 
Ser211 phosphorylation. A possible explanation for this 
could be the result of a conformational change in GR upon 
Ser203 phosphorylation, which hinders kinase access to 
Ser211. Our findings confirm Ser211 phosphorylation in 
PBMCs requires p38 MAPK activity, while findings from 
other studies would indicate that phosphorylation of Ser211 
may be a cell-type specific process.
In support of our findings, other studies have shown 
that GR phosphorylation on Ser211 enhances GR-mediated 
transcription.7,29,30 For example, in transformed cells it has 
been suggested that phosphorylation of Ser211 enhances GR-
mediated transcription by having an effect on the conforma-
tion of GR, rendering it more accessible to interaction with 
cofactors such as GR-interacting protein-1.31 Paradoxically, 
sustained, dysregulated phosphorylation of GR can impair 
GR function.32 Potential mechanisms of CS insensitivity 
resulting from hyper-phosphorylation of GR include reduc-
tion in: 1) GR–glucocorticoid response  element interaction; 
2) GR ligand binding affinity; and 3) GR recycling following 
nuclear export.7 Hyperphosphorylation has been shown to 
inhibit GR-mediated transcriptional activation, promote GR 
export from the nucleus upon hormone withdrawal,33 and alter 
cofactor recruitment to modulate the transcriptional response 
of GR to attenuate CS signaling.32 Direct involvement of 
Ser211 in these mechanisms requires further investigation.
Conclusion
Our study points to a novel approach to the treatment of 
COPD. A p38 MAPK inhibitor may not only be used as 
an anti-inflammatory agent, but it also induces reversal of 
CS insensitivity, which would lead to improved therapeutic 
effects of CS.
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